Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Pre-Market Trading 05-07 05:21:06 EDT

1.90

+0.01

+0.26%

High1.97	Low1.89	Vol1.37M
Open1.95	D1 Closing1.89	Amplitude4.50%
Mkt Cap280.94M	Tradable Cap273.07M	Total Shares148.25M
T/O2.62M	T/O Rate0.95%	Tradable Shares144.10M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":1.895,"timestamp":1715025600000,"preClose":1.89,"halted":0,"volume":1366677,"delay":0,"floatShares":144101120,"shares":148253615,"eps":-0.452188,"marketStatus":"Pre-Market Trading","change":0.005,"latestTime":"05-07 05:21:06 EDT","open":1.95,"high":1.97,"low":1.885,"amount":2620726.2850977,"amplitude":0.044974,"askPrice":2.04,"askSize":100,"bidPrice":1.73,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.452188,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1715088600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":1.895,"postHourTrading":{"tag":"盘后","latestPrice":1.9,"preClose":1.895,"latestTime":"19:27 EDT","volume":10116,"amount":19318.9924,"timestamp":1715038033936},"volumeRatio":1.2718894393777467},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2433421682","title":"BRIEF-Xeris Enters Into An Exclusive Worldwide Collaboration And License Agreement With Beta Bionics","url":"https://stock-news.laohu8.com/highlight/detail?id=2433421682","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433421682?lang=en_us&edition=fundamental","pubTime":"2024-05-06 19:37","pubTimestamp":1714995428,"startTime":"0","endTime":"0","summary":"May 6  - Xeris Biopharma Holdings Inc   :   * XERIS ENTERS INTO AN EXCLUSIVE WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH BETA BIONICS   * XERIS BIOPHARMA: POTENTIAL TO GET DEVELOPMENT PAYMENTS, PLUS LOW DOUBLE-DIGIT ROYALTIES BASED ON FUTURE SALES OF XERIS GLUCAGON FOR PUMPS, PUMP SYSTEMSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433424607","title":"Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424607","media":"ACCESSWIRE","top":-1,"share":"https://ttm.financial/m/news/2433424607?lang=en_us&edition=fundamental","pubTime":"2024-05-06 19:01","pubTimestamp":1714993260,"startTime":"0","endTime":"0","summary":"For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems.CONCORD, MA / ACCESSWIRE / May 6, 2024 / Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol technology for use in Beta Bionics' proprietary bi-hormonal pump and pump systems.Forward-Looking StatementsAny statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development and pote","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iiULiosxpahu8kNrvFtTxw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/51a607c01999677ec729ef773432260c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iiULiosxpahu8kNrvFtTxw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/51a607c01999677ec729ef773432260c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-enters-exclusive-worldwide-collaboration-110100316.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432809069","title":"Pleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2432809069","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432809069?lang=en_us&edition=fundamental","pubTime":"2024-05-02 23:24","pubTimestamp":1714663487,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Xeris Biopharma Holdings, Inc. , that sends out a positive message to the company's shareholders.While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.Check out our latest analysis for Xeris Biopharma Holdings. Xeris Biopharma Holdings Insider Transactions Over The Last Year. The Chief Financial Officer Steven Pieper made the biggest insider purchase in the last 12 months. That single transaction was for US$55k worth of shares at a price of US$1.95 each. That means that an insider was happy to buy shares at above the current price of US$1.75. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price inside","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pleasing-signs-number-insiders-buy-152447972.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432867201","title":"Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432867201","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432867201?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:00","pubTimestamp":1714647600,"startTime":"0","endTime":"0","summary":"CHICAGO, May 02, 2024----Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, May 23, 2024 at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 952508. Allison WeySenior Vice Pre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EVz2_DRw5H6Cs1LHjCNWrw--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cbfe914b90362929eacca77dd9f9ce02","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EVz2_DRw5H6Cs1LHjCNWrw--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cbfe914b90362929eacca77dd9f9ce02"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-report-first-quarter-110000089.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428791343","title":"Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2428791343","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428791343?lang=en_us&edition=fundamental","pubTime":"2024-04-17 19:24","pubTimestamp":1713353040,"startTime":"0","endTime":"0","summary":"MediWound  shares soared 14.3% in the last trading session to close at $18.28. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.7% gain over the past four weeks.Last month, the company announced robust financial results for the full year and fourth quarter ended 2023. This might have been driving the share price rally.This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $4.65 million, up 22.3% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.Xeris Biopharma Holdings, Inc.  : Free Stock Analysis Report. To read this article on Zack","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c7QYGIeMUDIp3mS1qSXkLA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/78361099d48178155a7388f9575187c7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c7QYGIeMUDIp3mS1qSXkLA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/78361099d48178155a7388f9575187c7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-mediwound-mdwd-14-112400418.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424729638","title":"Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2424729638","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2424729638?lang=en_us&edition=fundamental","pubTime":"2024-04-04 04:05","pubTimestamp":1712174700,"startTime":"0","endTime":"0","summary":"CHICAGO, April 03, 2024----Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee under Xeris’ Inducement Equity Plan.Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635 of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments, and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.sN8ouDMXhAjch9K6Iqx_Q--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0250714c66446e1be55ff380a256ec95","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.sN8ouDMXhAjch9K6Iqx_Q--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0250714c66446e1be55ff380a256ec95"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-pharmaceuticals-announces-inducement-grants-200500545.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424018348","title":"Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2424018348","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2424018348?lang=en_us&edition=fundamental","pubTime":"2024-04-02 19:00","pubTimestamp":1712055600,"startTime":"0","endTime":"0","summary":"Xeris  is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, a proven therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol and XeriJect, supporting long-term product development and commercial success.Allison WeySenior Vice President, Investor Relations and Corporate Communicationsawey@xerispharma.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R0e0ES5uTyi.Z5Qie6RteQ--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ffef3fb4d3b44c3357ac89e15d667ba4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R0e0ES5uTyi.Z5Qie6RteQ--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ffef3fb4d3b44c3357ac89e15d667ba4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-participate-23rd-annual-110000573.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423182471","title":"Xeris Biopharma: Checking-In On One Of My 'Top Ideas'","url":"https://stock-news.laohu8.com/highlight/detail?id=2423182471","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2423182471?lang=en_us&edition=fundamental","pubTime":"2024-03-30 13:28","pubTimestamp":1711776533,"startTime":"0","endTime":"0","summary":"Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a \"Top Idea\" in the Compounding Healthcare Investing Group.Xeris has three approved products and a strong pipeline, with p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4681270-xeris-biopharma-checking-in-on-one-of-my-top-ideas","is_publish_highlight":false,"gpt_icon":0},{"id":"2423435681","title":"Xeris gains as Oppenheimer highlights drug technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2423435681","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2423435681?lang=en_us&edition=fundamental","pubTime":"2024-03-29 01:11","pubTimestamp":1711645875,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  traded higher on Thursday after Oppenheimer launched its coverage with an Outperform rating and a $5 per share target, citing its drug formulation technologies, XeriSol and XeriJect. Designed to deliver subcutaneous or intramuscular treatments instead of intravenous infusions, XeriSol and XeriJect allow for convenient, cost-effective drug storage, improving the overall healthcare experience. Oppenheimer analyst Leland Gershell notes that the company has already attracted partnerships from Regeneron  and Amgen  with its XeriJect formulation, and more deals are likely on the horizon. Gershell argues that XeriJect has notable benefits compared to a similar technology from Halozyme . XERS's experimental therapy, XP-8121, based on XeriSol technology, is designed to overcome some of the key limitations in current hypothyroidism management.  Topline data for XP-8121 in hypothyroidism, expected in mid-2024 from a mid-stage study, \"will increase our confidence in this candidate","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/462756183/image_462756183.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/462756183/image_462756183.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085090-xeris-stock-gains-oppenheimer-bullish-view","is_publish_highlight":false,"gpt_icon":0},{"id":"2422492941","title":"ANGI, MLKN and KOD are among after hour movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422492941","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422492941?lang=en_us&edition=fundamental","pubTime":"2024-03-28 04:50","pubTimestamp":1711572631,"startTime":"0","endTime":"0","summary":"Gainers:Athira Pharma (ATHA) +5%.ContextLogic (WISH) +5%.Angi (ANGI) +4%.Xeris Biopharma Holdings (XERS) +4%.Inozyme Pharma (INZY) +3%.Losers:MillerKnoll (MLKN) -13%.Phathom Pharmaceuticals (PHAT) -5%.Kodiak Sciences (KOD) -5%.LENZ Therapeutics (LENZ) -5%.NewAmsterdam Pharma Company (NAMSW) -5%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4084685-angi-mlkn-and-kod-are-among-after-hour-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2418069438","title":"Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2418069438","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2418069438?lang=en_us&edition=fundamental","pubTime":"2024-03-11 12:40","pubTimestamp":1710132045,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Applied Therapeutics (APLT – Research Report), Xer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-applied-therapeutics-aplt-xeris-pharmaceuticals-xers-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-applied-therapeutics-aplt-xeris-pharmaceuticals-xers-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2418009623","title":"Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2418009623","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2418009623?lang=en_us&edition=fundamental","pubTime":"2024-03-09 22:14","pubTimestamp":1709993669,"startTime":"0","endTime":"0","summary":"There's been a major selloff in Xeris Biopharma Holdings, Inc.  shares in the week since it released its full-year report, with the stock down 26% to US$2.35. The statutory results were mixed overall, with revenues of US$164m in line with analyst forecasts, but losses of US$0.45 per share, some 3.7% larger than the analysts were predicting. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.Check out our latest analysis for Xeris Biopharma Holdings. The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Xeris Biopharma Holdings. Ha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-analysts-forecasting-xeris-biopharma-141429395.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417711304","title":"Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2417711304","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2417711304?lang=en_us&edition=fundamental","pubTime":"2024-03-08 02:47","pubTimestamp":1709837224,"startTime":"0","endTime":"0","summary":"Total Revenue: Q4 revenue surged by 34% year-over-year to over $44M; full-year revenue jumped 49% to approximately $164M.Net Loss: Q4 net loss narrowed to $13.4M ; full-year net loss stood at $62.3M .Cash Position: Ended 2023 with over $72M in cash, cash equivalents, and short-term investments.Commercial Products: Gvoke, Keveyis, and Recorlev showed strong sales performance, with Recorlev's Q4 revenue increasing by 157.6%.On March 6, 2024, Xeris Biopharma Holdings Inc  released its 8-K filing, announcing financial results for the fourth quarter and full year ended December 31, 2023. The company, known for its innovative therapies in endocrinology, neurology, and gastroenterology, including three commercially available productsGvoke, Keveyis, and Recorlevhas reported a significant increase in revenue and a positive cash flow for the last quarter of 2023.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qqMg9gW2eCCjWN.4sIUuKQ--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/50f20ebcbc1b7d34d67ea13f05b5cf40","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qqMg9gW2eCCjWN.4sIUuKQ--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/50f20ebcbc1b7d34d67ea13f05b5cf40"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-xers-184704684.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417759083","title":"Xeris Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2417759083","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2417759083?lang=en_us&edition=fundamental","pubTime":"2024-03-07 19:23","pubTimestamp":1709810580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2024 06:23 ET (11:23 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2417045412","title":"Q4 2023 Xeris Biopharma Holdings Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2417045412","media":"Thomson Reuters StreetEvents","top":-1,"share":"https://ttm.financial/m/news/2417045412?lang=en_us&edition=fundamental","pubTime":"2024-03-07 12:16","pubTimestamp":1709785003,"startTime":"0","endTime":"0","summary":"Allison Wey; SVP of IR & Corporate Communications; Xeris Biopharma Holdings, Inc.Paul Edick; Chairman & CEO; Xeris Biopharma Holdings, Inc.Thanks, Allison. Good morning, everyone, and thank you for joining us today. Let me start by thanking everyone who contributed in some meaningful way to us delivering an outstanding year for the Company, including the patients we serve, the health care providers we enable and the dedicated sales team that executes at a very high level every day. 2023 was an exceptional year of performance and growth reserves highlighted by our total revenue, which grew an impressive 49% from 2022 to $164 million in 2023 and ending 2023 with over $72 million in cash. This revenue growth, along with Xeris's strong cash position continues to demonstrate the sustainability of the enterprise we're building. In 2023, we significantly advanced our once weekly subcutaneous aerosol Levothyroxine program. We completed enrollment in our Phase 2 clinical study and have made con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2023-xeris-biopharma-holdings-041643039.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417213493","title":"Xeris Biopharma Shares Drop After Weak 4Q Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2417213493","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2417213493?lang=en_us&edition=fundamental","pubTime":"2024-03-06 23:41","pubTimestamp":1709739660,"startTime":"0","endTime":"0","summary":"Shares of Xeris Biopharma Shares dropped after the company's fourth quarter results came in below expectations.The stock was down 18% at $2.52 in recent trading. Shares are still up 8% year-to-date.The biopharmaceutical company's quarterly loss widened to $13.4 million from $12.9 million last year. Per share, the loss was 10 cents, a penny lower than the consensus estimate of analysts polled by FactSet.Product revenue jumped to $42.5 million from $32.5 million, missing analyst forecasts for $43.2 million, according to FactSet.Xeris provided guidance for $180 million to $200 million in revenue, which was in line with current analyst estimates.The Chicago-based company also said Wednesday that it refinanced a $150 million senior secured term loan facility with Hayfin Capital. Xeris drew down $200 million to repay its existing $150 million loan, raising the company's cash balance to about $35 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2417292181","title":"Xeris Biopharma Holdings Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2417292181","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2417292181?lang=en_us&edition=fundamental","pubTime":"2024-03-06 22:41","pubTimestamp":1709736119,"startTime":"0","endTime":"0","summary":"* Xeris Biopharma Holdings Inc    reported a quarterly adjusted loss of 10 cents per share for the quarter ended in December, identical to the same quarter last year.  The mean expectation of five ana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417184922","title":"Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2417184922","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2417184922?lang=en_us&edition=fundamental","pubTime":"2024-03-06 21:15","pubTimestamp":1709730904,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.09, delivering a surprise of 25%.Xeris Biopharma , which belongs to the Zacks Medical - Drugs industry, posted revenues of $44.39 million for the quarter ended December 2023, missing the Zacks Consensus Estimate by 2.44%. This compares to year-ago revenues of $33.14 million. The company has topped consensus revenue estimates three times over the last four quarters.Xeris Biopharma shares have added about 31.1% since the beginning of the year versus the S&P 500's gain of 6.5%.While Xeris Biopharma has outperformed the market so far this year, the question that comes to investor","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-xers-reports-q4-131504773.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417262558","title":"BRIEF-Xeris Refinances Its $150M Senior Secured Term Loan Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2417262558","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2417262558?lang=en_us&edition=fundamental","pubTime":"2024-03-06 20:14","pubTimestamp":1709727261,"startTime":"0","endTime":"0","summary":"March 6  - Xeris Biopharma Holdings Inc :   * XERIS REFINANCES ITS $150M SENIOR SECURED TERM LOAN FACILITY WITH HAYFIN CAPITAL   * XERIS BIOPHARMA HOLDINGS: GOT INTO AMENDED & RESTATED SENIOR SECURED TERM LOAN AGREEMENT WITH HAYFIN CAPITAL TO PROVIDE CO $200 MILLION CAPITAL AT CLOSESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.0829},{"period":"1month","weight":-0.0711},{"period":"3month","weight":-0.2822},{"period":"6month","weight":-0.0429},{"period":"1year","weight":-0.2104},{"period":"ytd","weight":-0.1936}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":-0.0036},{"period":"3month","weight":0.0457},{"period":"6month","weight":0.1814},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.0868}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.091365},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026041},{"month":3,"riseRate":0.5,"avgChangeRate":-0.107706},{"month":4,"riseRate":0.5,"avgChangeRate":0.063543},{"month":5,"riseRate":0.666667,"avgChangeRate":0.152525},{"month":6,"riseRate":0.6,"avgChangeRate":-0.082978},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.045103},{"month":8,"riseRate":0.5,"avgChangeRate":0.165434},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.094375},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.059108},{"month":11,"riseRate":0.5,"avgChangeRate":0.006729},{"month":12,"riseRate":0.5,"avgChangeRate":0.047808}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction